Perrigo receives final approval for generic Sanctura XR

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval for the generic version of Sanctura XR®. Perrigo had previously prevailed in litigation at both the district and appellate levels. The product has begun shipping immediately.

Sanctura XR® (Trospium Chloride Extended-release Capsules, 60 mg), is a once-daily medication for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency and has annual sales of approximately $54 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is another example of Perrigo's commitment to bring new products to market. Perrigo continues to deliver on its mission to provide quality, affordable healthcare to consumers."

Source:

Perrigo

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.